Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. See why I rate the CLOV stock a Buy.

Medicare Advantage (MA) insurer Clover Health is leaning on strong performance in the annual enrollment period and financial ...

Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income ...

In the past week, former President Donald Trump proposed a one-year 10% cap on US credit card interest rates, raising ...

Synchrony Financial SYF recently announced an enhanced integration with Clover, the comprehensive commerce platform from ...

Clover Health Investments shares rose after the company said it expected to turn a profit in 2026 following a strong Medicare Advantage enrollment period. Shares were up 11% to $2.82 in Wednesday ...

The two payments processors have the biggest market shares with respect to smaller restaurants, according to a new report ...

Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 10% in the afternoon session after the company ...

Clover Health InvestmentsCLOV has reported strong results from the 2026 Annual Enrollment Period (AEP), delivering 53% ...

(NASDAQ: FISV), a leading global provider of payments and financial services technology, today announced a new strategic partnership with Sumitomo Mitsui Card Company, Limited (SMCC) to bring Fiserv's ...

We came across a bullish thesis on Clover Health Investments, Corp. on topsecretstocks’s Substack. In this article, we will ...

Clover maintained stable plan benefits year-over-year, resulting in over 95% AEP member retention. More than 97% of the company’s January 1, 2026 Medicare Advantage membership is enrolled in its ...